EZR and breast carcinoma: Other studies showed the ability of ezrin to augment oncogenic EGFR and HER2 signaling in non–small cell lung cancer and breast cancer cells, respectively, while pharmacologic inhibition of ezrin with the same small molecules initially identified by Bulut and colleagues (8), synergistically enhanced erlotinib- and lapatinib-mediated killing of tumor cells (32, 33).